MedTrace Logo

A Study of Zigakibart in Adults With IgA Nephropathy

NCT05852938 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 383

Last updated 2026-04-01

No results posted yet for this study

Summary

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

Conditions

Interventions

DRUG

BION-1301

BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.

DRUG

Placebo

Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2027-08-10
Completion
2028-01-25
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • China
  • Croatia
  • Czechia
  • France
  • Germany
  • Greece
  • India
  • Israel
  • Italy
  • Japan
  • Malaysia
  • Mexico
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05852938 on ClinicalTrials.gov